Caladrius Biosciences Treats First Patient in the Phase 1b Trial of CLBS201 for the Treatment of Diabetic Kidney Disease
April 12, 2022 08:00 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 22, 2022 16:05 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 22, 2022, at 4:30 p.m. Eastern Time
March 15, 2022 08:00 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences Receives $2.3 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program
March 01, 2022 08:00 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences to Present at the BIO CEO & Investor Conference
February 08, 2022 16:05 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences Announces Participation in Upcoming Conferences in January 2022
January 04, 2022 16:05 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences Provides Corporate Update and Reports 2021 Third Quarter Financial Results
November 04, 2021 16:05 ET
|
Caladrius Biosciences, Inc.
Company Reports Strong Cash Position as it Prepares to Initiate a CD34+ Cell Therapy Study in Diabetic Kidney Disease Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J.,...
Caladrius Biosciences to Host Third Quarter 2021 Financial Results Conference Call on Thursday, November 4th at 4:30 p.m. Eastern Time
October 28, 2021 08:00 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences Announces Participation in Upcoming Conferences in October 2021
October 04, 2021 08:00 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021 08:00 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...